U.S. Office REITs Stock News

If you are wondering whether Yum! Brands stock still offers value at around US$157.67, the key question is how that price compares with what the business may be worth. The share price recently closed at US$157.67, with total returns of 4.0% over the past week, 5.1% over the past month, 4.8% year to date, 14.8% over 1 year, 23.0% over 3 years, and 47.4% over 5 years. Recent attention on Yum! Brands has centered on how the company is positioned in the quick service restaurant space and what...

Blackstone Mortgage Trust (BXMT) drew fresh attention after its recent trading session, with the stock closing at $18.34. Investors are reassessing the mortgage REIT’s income profile and risk exposure in commercial real estate lending. See our latest analysis for Blackstone Mortgage Trust. Looking beyond the latest move to $18.34, Blackstone Mortgage Trust has seen mixed momentum, with the share price return down 5.85% year to date but a 1 year total shareholder return of 6.38% and 3 year...

CRH plc recently announced that former CF Industries CEO Tony Will, an experienced industrial and board leader with a background across manufacturing, consulting and transportation, will join its Board of Directors effective July 1, 2026. His blend of heavy-industry operating experience and current role on Union Pacific’s board adds expertise in large-scale capital allocation, logistics and governance that could influence CRH’s long-term decision-making. We’ll now examine how Tony Will’s...

Oracle stock reacts as investors reassess recent performance Oracle (ORCL) stock is drawing attention as investors weigh its recent share performance against the company’s current financial profile, which includes revenue of US$67.36b and net income of US$16.98b. See our latest analysis for Oracle. At a share price of US$188.33, Oracle has seen its share price return fall 2.24% over the past day and 8.49% over the past week. However, its 90 day share price return of 23.17% and 3 year total...

Earlier in June 2026, BeOne Medicines reported extensive new data at the European Hematology Association Congress showing BRUKINSA, tacabrutideg and BEQALZI delivering durable responses and favorable safety profiles across multiple B‑cell malignancies, alongside long-term outcomes in very elderly CLL/SLL patients and large real‑world datasets supporting BRUKINSA’s clinical performance. The breadth of late-stage and real-world evidence, combined with regulatory designations such as FDA Fast...

SpaceX stock reaction to index additions and AI push Space Exploration Technologies (SPCX) has moved rapidly from its record US$75b IPO into key benchmarks, with fresh inclusion in the NASDAQ Telecom Index spotlighting its mix of satellite connectivity, launch services, and AI infrastructure. For you as an investor, that index entry matters because it can pull in rule based buying from funds that track the benchmark. At the same time, the company’s US$60b Cursor acquisition and large AI...

The United States market has experienced a 2.3% increase over the last week and a significant 25% rise in the past year, with earnings projected to grow by 19% annually. In such an environment, identifying stocks that may be priced below their intrinsic value can offer potential opportunities for investors seeking to capitalize on undervaluation amidst robust market growth.

Over the last 7 days, the United States market has risen by 2.3%, contributing to a robust 25% increase over the past year, with earnings forecasted to grow by 19% annually. In this thriving environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those closest to the business in its potential for future success.

The United States market has experienced a robust climb, with a 2.3% increase in the last week and a significant 25% rise over the past year, while earnings are projected to grow by 19% annually. Amidst these favorable conditions, identifying stocks that combine affordability with growth potential is key, especially when considering penny stocks. Although the term 'penny stock' might seem outdated, these smaller or newer companies can still offer substantial opportunities for investors who...

Recent analyst coverage of Parker-Hannifin (PH), including a new positive rating from Bernstein and an upside catalyst watch from Citi, has coincided with renewed interest following bullish technical signals in the stock. See our latest analysis for Parker-Hannifin. At a share price of $938.51, Parker-Hannifin has seen momentum pick up recently, with a 1-month share price return of 8.79% and a year-to-date share price return of 4.98%. Over the longer term, total shareholder returns of 45.15%...

US manufacturing stocks are back in focus as fresh tariff proposals, trade investigations, and the prospect of a new US-China Board of Trade reshape expectations for supply chains and costs. For investors, the question is which US Domestic Manufacturing Stocks could potentially benefit from this policy turn and which might face pressure as trade relationships evolve. This article highlights 3 stocks from the screener that are directly exposed to these trade headlines, explaining how the same...

Earlier in June 2026, Bruker Corporation filed an omnibus shelf registration covering a wide range of securities and showcased expanded infectious disease diagnostics capabilities, including new FDA-cleared enhancements for its MALDI Biotyper CA System and advanced workflows for rapid antimicrobial susceptibility testing. By pairing a broad financing toolkit with an enlarged microbiology and molecular diagnostics portfolio, Bruker is signaling both product ambition and flexibility in how it...

W.W. Grainger (GWW) has drawn attention after recent trading, with the stock last closing at $1,319.72. Investors are weighing this move against its recent performance and the company’s current fundamentals. See our latest analysis for W.W. Grainger. Recent trading in W.W. Grainger sits against a backdrop of strong momentum, with a 30 day share price return of 3.71% and a 90 day share price return of 26.19%, while the 5 year total shareholder return of 213.89% points to a robust longer term...

Agios Pharmaceuticals (AGIO) stock is back in focus after the company shared detailed 52 week data from its RISE UP Phase 3 trial of mitapivat in sickle cell disease at EHA 2026. See our latest analysis for Agios Pharmaceuticals. Agios Pharmaceuticals shares have recently picked up momentum, with a 7 day share price return of 10.25% and a 30 day share price return of 12.87%. However, the 1 year total shareholder return is still down 10.31%, showing short term enthusiasm against a mixed longer...

Recent commentary around Halozyme Therapeutics (HALO) has centered on its collaborations with large pharmaceutical partners and its use of recombinant human hyaluronidase technology to broaden injectable biologic delivery and expand global reach. See our latest analysis for Halozyme Therapeutics. Recent updates around Medicare drug price negotiations and technical trading signals have coincided with Halozyme Therapeutics’ 10.07% 90 day share price return and a 31.03% 1 year total shareholder...

LPL Financial Holdings (LPLA) has drawn fresh attention after reporting May 2026 metrics that showed 3.1% growth in total client assets, with advisory assets reaching 60.2% of the total, alongside $8.8 billion in organic net new assets. See our latest analysis for LPL Financial Holdings. The recent May asset update and the addition of new advisory teams have come alongside a 6.29% 90 day share price return, even as the year to date share price return is down 16.13% and the 1 year total...

If you are wondering whether Eli Lilly stock still offers reasonable value after its huge run, this article will walk through what the current price might be implying. The stock trades around US$1,122.50, with returns of 11.7% over the past month, 3.9% year to date, 42.9% over the past year, very large gains over three years and around 7x over five years. This naturally raises questions about growth expectations and risk. Recent headlines around Eli Lilly have centered on its position in...

On 10 June 2026, GitLab expanded its collaboration with Google Cloud to offer a managed, sovereign DevSecOps platform and unveiled new AI-powered features like Next Generation Source Code Management, GitLab Orbit, and enhanced agent governance to support large-scale, compliant software delivery. A distinctive angle is GitLab’s push to combine fast, token-efficient AI agents with fine-grained security and compliance controls, directly targeting heavily regulated enterprises that need both...

Macerich (MAC) stock has drawn investor attention after its recent performance, with the share price closing at $23.75 and total return figures highlighting a mix of shorter and longer term outcomes. See our latest analysis for Macerich. Recent trading has been choppy for Macerich, with the share price falling 5.34% over the last day even after a 30 day share price return of 9.95% and a year to date share price return of 28.24%. The 1 year total shareholder return of 55.45% and 3 year total...

Dynatrace (DT) is back in focus after multiple major banks, including UBS, initiated or upgraded coverage with positive commentary on its AI observability platform and potential for improved revenue performance. See our latest analysis for Dynatrace. The recent upgrades have come alongside a 30 day share price return of 8.08% and a 90 day share price return of 3.03%, even as the 1 year total shareholder return is down 25.83%. This indicates near term momentum against a weaker longer term...

Benchmark's Benjamin Klieve recently reiterated a positive view on Andersons (ANDE) and raised earnings estimates after management outlined a supportive macro backdrop and growth opportunities during a non-deal roadshow with investors. See our latest analysis for Andersons. At a share price of $69.21, Andersons has given investors a year to date share price return of 30.46%, while its 1 year total shareholder return of 89.30% and 5 year total shareholder return of 150.23% point to momentum...

Deere recently reported a strong first-quarter performance, with revenues surpassing analysts’ expectations and especially strong results in its Small Agriculture and Construction & Forestry divisions. At the same time, a US$99 million settlement over repair restrictions and investor commentary on an improving downcycle backdrop underscored how Deere’s diversified model and evolving customer relationships are shaping its longer-term business profile. We’ll now explore how Deere’s...

Earlier this month, CRISPR Therapeutics AG filed a shelf registration for up to US$969.16 million in common shares tied to an ESOP-related offering, while shareholders approved amendments to the company’s articles of association at the June 4, 2026 annual meeting. Against a backdrop of earnings estimate revisions, revenue growth expectations, and a valuation premium versus peers, these capital and governance moves come as investors reassess CRISPR Therapeutics’ long‑term profile and...

MBX Biosciences (MBX) has drawn fresh attention after publishing full Phase 2 Avail and one-year open-label data for its lead candidate canvuparatide in chronic hypoparathyroidism, alongside confirming plans for a pivotal Phase 3 trial. See our latest analysis for MBX Biosciences. Against this backdrop, MBX Biosciences stock has seen strong momentum, with a 7 day share price return of 29.36% and a 90 day share price return of 41.01%, while the 1 year total shareholder return is very large at...